$PFE
Pfizer Inc.
Global pharmaceutical company known for vaccines and oncology treatments.
PFE key facts as of November 14, 2026
- Latest AI research report
- PFE Stock: Earnings, Yield and Patent Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Hold (1 Strong Buy, 8 Buy, 17 Hold, 1 Sell, 1 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $31.50 mean (range $27.00 to $40.00) (as of November 17, 2026)
- Sector
- Healthcare
Analysis from Nov 13, 2026
PFE Stock: Earnings, Yield and Patent Risks
Pfizer beat Q3 estimates and raised its 2026 revenue forecast, yet the shares remain weighed down by declining earnings trends and patent-expiration concerns. Here’s a balanced look at the dividend, valuation, analyst expectations and upcoming risks.
Previous Reports
PFE FAQ
What is StockAlpha's latest view on PFE?
StockAlpha's latest AI research report on Pfizer Inc. (PFE), "PFE Stock: Earnings, Yield and Patent Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Pfizer beat Q3 estimates and raised its 2026 revenue forecast, yet the shares remain weighed down by declining earnings trends and patent-expiration concerns. Here’s a balanced look at the dividend, valuation, analyst expectations and upcoming risks.
When was the PFE research last updated?
The most recent PFE report was published on November 14, 2026.
What do analysts expect for PFE?
As of November 1, 2026, the analyst consensus on PFE is Hold (1 Strong Buy, 8 Buy, 17 Hold, 1 Sell, 1 Strong Sell). As of November 17, 2026, the analyst price target is $31.50 mean (range $27.00 to $40.00).
Is this PFE research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Pfizer into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Pfizer's peers: Today's sector-level news and moves around the stock